Population colorectal cancer screening in the Czech Republic
Authors:
prof. MUDr. Ph.D. Miroslav Zavoral 1; MUDr. Gabriela Vojtěchová 1; RNDr. Ph.D. Ondřej Májek 2; Mgr. Ondřej Ngo; MUDr. Tomáš Grega; doc. MUDr. Ph.D. Bohumil Seifert; doc. RNDr. Ph.D. Ladislav Dušek; MUDr. Ph.D. Štěpán Suchánek
Authors‘ workplace:
Interní klinika 1. LF UK a ÚVN Praha
1; Institut biostatistiky a analýz Masarykovy univerzity v Brně
2; Ústav všeobecného lékařství 1. LF UK a VFN v Praze
3
Published in:
Čas. Lék. čes. 2016; 155: 7-12
Category:
Original Article
Overview
Colorectal cancer (CRC) is the third most common malignant disease in developed countries and its incidence is steadily growing. This trend has a stable character despite the fact that CRC is among the best prevention influenced malignancies. National CRC screening program in the Czech Republic, which was established in year 2000, follows the world trends resulting from evidence based medicine. Currently, the basic tools of screening program are immunochemical fecal occult blood tests and colonoscopy in case of their positivity or screening colonoscopy. Stagnation of participating population resulted to initiation of address invitation of the target population in January 2014, in which citizens are regularly invited to attend the screening program and their response is subsequently evaluated. Screening that impacts whole target group is called population screening.
Key words:
colorectal cancer, population screening program, colonoscopy, fecal occult blood tests, address invitation
Sources
1. Conteduca V, Sansonno D, Russi S et al. Precancerous colorectal lesions (Review). Int J Oncol 2013; 43: 973–984.
2. Dušek L, Májek O, Blaha M, Daneš J, Zavoral M et al. Koncepce populačního screeningu v České republice, metodika a první výsledky adresného zvaní občanů do preventivních onkologických programů. Klin Onkol 2014; 27 (Suppl 2): 2S59–2S68.
3. Ferlay J, Soerjomataram I, Ervik M et al. Globocan 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, 2013. URL: http://globocan.iarc.fr
4. Deyhle P. Colonic cancer-diagnosis, check-up, prevent. Internist (Berl) 1979; 20: 39–43.
5. Zavoral M, Suchánek S, Závada F et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009; 15: 5907–5915.
6. Brenner H, Hoffmeister M, Brenner G et al. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer 2009; 45: 2027–2033.
7. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345–2357.
8. Atkin W, Kralj-Hans I, Wardle J et al. Colorectal cancer screening. Randomised trials of flexible sigmoidoscopy. BMJ 2010; 341: c4618.
9. Johnson CD, Chen MH, Toledano AY et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 359: 1207–1217.
10. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365–1371.
11. Rabeneck L, Rumble RB, Thompson F et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012; 26: 131–147.
12. Bowyer HL, Vart G, Kralj-Hans I et al. Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of colorectal cancer. J Med Screen 2013; 20: 149–156.
13. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001; 37: 398–401.
14. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624–1633.
15. Robb K, Power E, Kralj-Hans I et al. Flexible sigmoidoscopy screening for colorectal cancer: uptake in a population-based pilot programme. J Med Screen 2010; 17: 75–78.
16. Segnan N, Patnick J, Von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis (1st ed.). European Union, 2010: 206–232.
17. Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010 May 13; 362(19): 1795–1803.
18. Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012 Feb 23; 366(8): 697–706.
19. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008 Jul; 135(1): 82–90.
20. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014 Apr 3; 370(14): 1287–1297.
21. Zavoral M, Májek O, Tachecí I, Beneš M, Drastich P, Vojtěchová G et al. Porovnání účinnosti kolonické kapslové endoskopie a kolonoskopie v detekci polypů a karcinomů tlustého střeva a konečníku – multicentrická, prospektivní, cross-over studie. Gastroent Hepatol 2014; 68(3): 218–224.
22. Holleran G, Leen R, O'Morain C et al. Colon capsule endoscopy as possible filter test for colonoscopy selection in a screening population with positive fecal immunology. Endoscopy 2014 Jun; 46(6): 473–478.
23. Krämer HU, Müller H, Stegmaier C et al. Type 2 diabetes mellitus and gender-specific risk for colorectal neoplasia. Eur J Epidemiol 2012; 27: 341–347.
24. Suchánek Š, Májek O, Grega T, Ngo O, Mináriková P, Brogyuk N, Seifert B, Dušek L, Zavoral M. Cílený screening kolorektálního karcinomu u diabetiků 2. typu a osob s vysokým kardiovaskulárním rizikem – první průběžné výsledky multicentrické prospektivní studie. Gastroent Hepatol 2014; 68(5): 411–416.
25. Kaminski MF, Polkowski M, Kraszewska E et al. A score to estimate the likelihood of detecting advanced colorectal neoplasia at colonoscopy. Gut 2014 Jul; 63(7): 1112–1119.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Pancreatic cancer – current effective diagnostic and therapeutic approach
- Malignant biliary obstruction
- Professor Josef Marek - octogenarian
- Foregut diseases: foregut neoplasms